Citadel Advisors
BBIO icon

Citadel Advisors’s BridgeBio Pharma BBIO Stock Holding History

Citadel Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$236M Buy
3,173,940
+2,475,758
+355% +$179M 0.04% 387
2025
Q4 		$53.4M Buy
+698,182
New +$45.8M 0.01% 1350
2025
Q3 		– Sell
-332,325
Closed -$16.2M – 12753
2025
Q2 		$14.3M Sell
332,325
-2,598,708
-89% -$94.5M ﹤0.01% 2570
2025
Q1 		$101M Buy
2,931,033
+1,675,672
+133% +$56.5M 0.02% 692
2024
Q4 		$34.4M Sell
1,255,361
-1,686,753
-57% -$43.6M 0.01% 1612
2024
Q3 		$74.9M Buy
2,942,114
+785,665
+36% +$20.6M 0.01% 913
2024
Q2 		$54.6M Buy
2,156,449
+1,273,174
+144% +$34.8M 0.01% 1083
2024
Q1 		$27.3M Buy
883,275
+219,120
+33% +$7.45M 0.01% 1758
2023
Q4 		$26.8M Buy
664,155
+95,495
+17% +$2.87M 0.01% 1728
2023
Q3 		$15M Buy
568,660
+155,050
+37% +$4.4M ﹤0.01% 2189
2023
Q2 		$7.11M Buy
413,610
+126,878
+44% +$1.91M ﹤0.01% 3133
2023
Q1 		$4.75M Sell
286,732
-2,590,456
-90% -$30.2M ﹤0.01% 3907
2022
Q4 		$21.9M Buy
2,877,188
+1,066,176
+59% +$10.2M 0.01% 1871
2022
Q3 		$18M Buy
1,811,012
+969,218
+115% +$10.1M ﹤0.01% 1996
2022
Q2 		$7.64M Buy
841,794
+455,732
+118% +$3.81M ﹤0.01% 3051
2022
Q1 		$3.92M Buy
+386,062
New +$3.96M ﹤0.01% 4651
2021
Q4 		– Sell
-342,548
Closed -$14.5M – 13788
2021
Q3 		$16.1M Sell
342,548
-70,030
-17% -$3.75M ﹤0.01% 2325
2021
Q2 		$25.1M Buy
412,578
+227,093
+122% +$13M 0.01% 1812
2021
Q1 		$11.4M Sell
185,485
-48,798
-21% -$3.19M ﹤0.01% 2779
2020
Q4 		$16.7M Buy
234,283
+120,665
+106% +$5.82M ﹤0.01% 2008
2020
Q3 		$4.26M Buy
113,618
+66,634
+142% +$2.1M ﹤0.01% 3388
2020
Q2 		$1.53M Buy
46,984
+14,616
+45% +$445K ﹤0.01% 5031
2020
Q1 		$939K Buy
+32,368
New +$1M ﹤0.01% 5453
2019
Q3 		– Sell
-22,281
Closed -$601K – 9146
2019
Q2 		$601K Buy
+22,281
New +$607K ﹤0.01% 6536

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's BBIO Position: Q1 2026 in Review

Citadel Advisors increased its BridgeBio Pharma (BBIO) stake by 355% in Q1 2026, buying an estimated $179M and bringing the position to 3,173,940 shares worth $236M. The position accounts for 0.04% of the portfolio, ranked #387.

Citadel Advisors first reported a position in BBIO in Q2 2019 and has held it in 24 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Citadel Advisors held 3,173,940 shares of BridgeBio Pharma worth $236M as of Q1 2026.
  • Citadel Advisors bought 2,475,758 BridgeBio Pharma shares in Q1 2026, an estimated $179M.
  • BridgeBio Pharma made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #387 holding.
  • Citadel Advisors first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 24 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.